SUPPLEMENTARY TABLES
. Published miR-9 targets. Including tissue/cell line where it was experimentally validated, assay used for validation, and references to the report where validated. This list excludes targets validated only from high-throughput methods i.e. microarray or CLIP-seq. gene cell type reference validation PRDM1
Hodgkin lymphoma Nie et al. [22] other BCL6
immunity Zhang et al. [39] other NFKB1
monocytes Asirvatham et al. [2] reporter assay POU2F2 immunity Forrest et al. [7] other ALCAM hepatoma Wang et al. [32] luciferase assay NR2E1
brain Denli et al. [6] other REST brain Packer et al. [24] other BACE1
brain Hébert et al. [9] reporter assay FOXP1 spinal cord Otaegi et al. [ human monoblast leukemia cells Forrest et al. [7] other AP3B1
human breast cancer cell line Selcuklu et al. [30] reporter assay CCNG1 human breast cancer cell line Selcuklu et al. [30] reporter assay LARP1 human breast cancer cell line Selcuklu et al. [30] reporter assay MTHFD1L human breast cancer cell line Selcuklu et al. [30] reporter assay MTHFD2 human breast cancer cell line Selcuklu et al. [30] reporter assay SRPK1 human breast cancer cell line Selcuklu et al. [30] reporter assay ELAVL1
HL cells and xenograft [15] WB, luciferase, IHC and pull-out assay DICER1
HL cells and xenograft [15] WB, luciferase, IHC and pull-out assay MALAT1 HL cells [16] WB, luciferase, IHC and pull-out assay 
SUPPLEMENTARY RESULTS:
Additional functional cluster descriptions: cluster 16: The fourth largest cluster, (N=264) showed a highly enriched TF target gene set for TFCP2 (p=1E-3). It showed Reactome enrichment for integrin cell surface interactions (p=7E-4) and Kegg enrichment for cell junctions (p=5E-4). It was enriched for cytokine genes (p=6E-3), including interleukin members such as IL-3. It did not show enrichment for particular RBP target genes. It showed a downward peak at 32 hours, suggesting that TFCP2 is acting as a negative regulator for these targets. cluster 18: The fifth largest cluster (N=141) was highly enriched for the TF ELF28 (p=3E-4). It showed enrichment for antigen processing and presentation immune genes (p=3E-3; Immport set). It was very highly enriched in AGO2* (p=1E-8; PAR-CLIP). KEGG enrichment showed focal adhesion (5E-4) and GO enrichment showed antigen processing and presentation of exogenous peptide antigen (p=4E-4). cluster 13: Cluster 13 (N=70) has a similar shape to cluster 14, and it is also enriched in splicing-related SFRS1 (aka SF2/ASF) targets (p=4E-4) and to a lesser extent AGO2 (p=0.01). It appears to have somewhat distinct functional enrichments to cluster 13 however with Reactome: golgi associated vesicle biogenesis (p=4E-05 ) and GO: glycolipid metabolic process (p=6E-05). cluster 3089: Cluster 3089 (N=37) is enriched in ELAV1 (p=4E-7); IGF2BP (p=1E-5) and QKI* (p=3E-3) RBP targets. The most significant TF target enrichment was for NR3C1* (p=7E-4). It shows GO enrichment for proteolysis (p=3E-4; GO). Apart from cluster 1, cluster 3089 is the only one to show highly significant ARE enrichment (class C3; p=8E-3). Interestingly, the curve shape resembles that of cluster 1, and is enriched above background for miR-9 seeds, although this does not reach statistical significance. This cluster probably represents a smaller cluster of direct targets with an alternative dynamic response. The known TF miR-9 target Onecut-2* noted previously is included in this cluster; it has been shown that in beta-cells miR-9 down-regulates the TF Onecut-2 which, acting as a transcriptional repressor, therefore increasing the expression of Sytl4 (Granuphilin/Slp4) [26] (see next section). cluster 3611: Cluster 3611 (N=8) similarly has a curve shape resembling cluster 1. It is significantly enriched in miR-9 7-mer seeds (p=0.02), and probably also represents a smaller distinguished cluster of miR-9 direct targets. It is enriched in ELAV1 targets (p=1E-5), and is enriched in tRNA 3' end processing (p:4E-4) (GO). cluster 2744: Cluster 2744 (N=18) shows striking enrichment for cytokine genes (p=3E-5); it shows a peak at 12 hours consistent with the enrichment for cytokine genes seen in fig 3 (E), consistent with downstream indirect regulation. It is enriched for transcription factor targets of KLF12* (p=6E-3) and LEF1 (p=7E-3). cluster 2718: Cluster 2718 (N=34) is enriched in translational functions: Reactome translation (p=5E-5); Kegg ribosome (7E-06 ); GO translational elongation (3E-05 ); GO ribosomal subunit (3E-05). Genes known to be coregulated with TPT1* and NPM1 are enriched (MSigDB) (TPT1; p=6E-06); (NPM1; 3E-05 ). E2F1 transcription factor target motifs are enriched (p=2E-4). It shows a delayed major peak at approximately 40 hours, and so may represent a response to increase translation of downstream regulated genes. cluster 3118: Cluster 3118 (N=22) has a similar curve response to cluster 18, and is enriched in immunity-related targets with enrichment in natural killer cell cytotoxicity (p=1E-2; Immport) and Kegg: natural killer cell mediated cytotoxicity (p=1E-2). cluster 3445: Cluster 3445 (N=8) is highly enriched in AGO2 target genes (p=8E-6). It shows functional enrichments in Reactome: RNA polymerase III chain elongation (p=4E-3) and microRNA biogenesis (p=7E-3). cluster 2967: Cluster 2967 (N=35) is enriched for the VIP/ADCYAP1 pathway (1E-5). PACAP is known to be expressed in the lymphoid microenvironment to modulation of innate and adaptive immunity, and inhibits apoptosis of activated T cells, and the VIP/PACAP pathway is known to down-regulate NFκ-beta. Interestingly, NFKB1 itself is included in this cluster. There is enrichment for the BCR signalling pathway (Biocarta: p=7E-3); additional functional enrichments include: Kegg: apoptosis (p=5E-4); B cell receptor signalling pathway (p=6E-3). cluster 2981: Cluster 2981 has a similar shape to cluster 2967 and is involved in negative regulation of mast cell apoptosis (GO: p=0.005). cluster 3185: Cluster 3185 (N=22) is annotated as highly enriched for MTF1 target genes (p=5E-5); the closely related MTF2* is a high confidence miR-9 target. Figure 4 : Mean FC response curves over transcription factor REST targets. Red: TF gene response; Black: mean TF target genes response. TF gene REST is a predicted miR-9 direct target and a known transcriptional repressor. Consistent with being a transcriptional repressor, the mean curve of its target genes shows a negative response at 32 hours. The transcription factor REST (aka NRSF) is a candidate component in a coherent feed-back mechanism involving miR-9. It is involved in validated examples of positive feedback involving miR-9 in other tissues. Notably, it is a predicted miR-9 direct target and is known to regulate miR-9 promoters to cause transcriptional gene silencing by histone acetylation; miR-9-1 and miR-9-2 promoters have been reported as REST targets in human, and all three paralogs in mouse [4, 14, 24] . This feedback cycle could hypothetically lead to a coherent upward response downstream after miR-9 inhibition, with the initial de-repression of miR-9 target REST leading to a later, approximately 32 hour, amplified de-repression of miR-9 targets due to transcriptional REST repression of miR-9 genes. Grey bands are 1 SEM. Analysis restricted to expressed genes showing ≥ 1.5 FC at some time point. TF target genes computationally predicted by promoter motif search [17] . [27] to LNA versus control microarray files, separately at each time point. Geneset enrichment analysis was performed based on the resulting gene alternative splicing statistic for the genesets of the Biocarta pathways database. (B) Metabolic labelling assay to measure protein production following the miR-9 inhibition. Y-axis is counts per minutes (CPM) normalised to total protein load and error bars show standard error of 3 biological replicates (p=0.0148; t-test). Decreased protein metabolism following miR-9 inhibition relative to controls is consistent with mTOR pathway perturbation. Changes in global translational rates were measured by monitoring the incorporation of 35S-labeled methionine (PerkinElmer), as previously described [3] . Metabolic labelling of L428 cells used 35S methionine. L428 cells were treated with a miR-9 inhibitor or control (3 biological replicates). Cells were assayed 24 hours after transfection. Counts per minute (CPM) were normalised to total protein load. Several miRNA families as well as miR-9 showed statistically significant enrichment: we hypothesise that these represent co-targetting of miR-9 target genes by these other miRNAs in HL, as well as potential confounding by an increased overall 3 UTR length of miR-9 targets. It has been noted that genes that are regulated by one family of miRNA are often combinatorially regulated by other families of miRNAs (target "hub" genes) [2, 7, 31, 33, 36, 38] . Indeed, we found that those genes with seeds matching these statistically enriched miRNA families also showed a significantly higher overlap with miR-9 target genes compared with other miRNAs (p=1E-5).
(B) Ratio of number of significant TF to miRNA motifs across time. At 4 hours are significantly enriched miRNA seed motifs but no significant TF motifs; 14 hours shows substantial enrichment of TF motifs relative to miRNA seeds.
